News

HRPP Response to COVID-19

  HRPP Response to COVID-19 Public Health Emergency  Since the beginning of the COVID emergency, the Human Research Protections Program has made rapid adjustments to support the research community.

COVID-19 Information for Researchers

Human Research Protection Program March 25, 2020 To: Investigators and Staff COVID-19 Information for Researchers Dear Colleagues,

New iMedRIS email for iRIS notifications

Add [email protected] to Outlook “Safe Senders” List  Updated 12/18/19: This bulletin has been updated to include instructions for Mac and OWA users.  

Transition of Management of Affiliate Access for Research Personnel to PI Departments

The information included in this message is a follow-up message regarding the IRB bulletin sent on 8/5/19. Beginning August 12th, the UCSF IRB will no longer manage affiliate access requests and extensions for non-UCSF research personnel who work on UCSF-faculty-supervised research. Moving forward…

IRB News: Changes in Affiliate Access

IRB News, Changes in affiliate access Starting August 12th, 2019, the IRB will no longer sponsor or coordinate Affiliate Access for the iRIS online IRB system.

July Updates

To: Investigators and Staff Re: IRB News, Changes in requirements and reporting The following notice provides updates regarding the new Common Rule requirements, Recombinant DNA Advisory Committee review, and iRIS (IRB submission system) guidance.

Common Rule & New Application

  Human Research Protection Program February 4th, 2019 To: Investigators and Staff Revised Common Rule

IRB Regulatory Changes coming January 21, 2019

Human Research Protection Program December 19, 2018 To: Investigators and Staff Re: IRB Regulatory Changes coming January 21, 2019 IRB Regulatory Changes coming January 21, 2019

Clinical Research Operations Update From Lindsey Criswell, Vice Chancellor of Research

Clinical Research Operations Update From Lindsey Criswell, Vice Chancellor of Research June 2018 We understand that one of our top areas for improvement continues to be the time it takes for investigators to initiate clinical trials, and as such, this is an active area of focu